The power of genomics in transforming the biotechnology industry will be evident in all areas of drug discovery and development. This will be particularly true in safety evaluation, where the field will be forced to adapt to new schemes of e-R&D and e-business in general. Toxicologists will be required to create information-rich, real-time systems that can be used for decisions in the earliest phases of discovery and throughout development. The largest growth area in specific product types will be those that can move genomics information from the laboratory to the clinic the fastest.
Cavagnaro, J. A.1997. Considerations in the preclinical safety assessment of biotechnology-derived products. In Comprehensive toxicology, Vol. 2, toxicological testing and evaluation, eds. P. D. Williams and G. H. Hottendorf, 291–298. New York: Elsevier Science.
2.
Dempster, A. M.2000. Nonclinical safety evaluation of biotechnology derived Pharmaceuticals. Biotechnol. Annu. Rev.5:221–258.
3.
Drews, J.2000. Drug discovery: A historical perspective. Science287:1960–1964.
4.
Griffiths, S. A., and C. E. Lumley.1998. Safety evaluation of biotechnologically-derived pharmaceuticals: Facilitating a scientific approach.Dordrecht, The Netherlands: Kluwer Academics.
5.
Henry, C. M.2000. The next pharmaceutical century. Chem. Engineer. News78:85–100.
6.
Hoogenboom, H. R., and P. Chames.2000. Natural and designer binding sites made by phage display technology. Immunol. Today8:371–378.
7.
Johnson, D. E., P. E. Blower, G. J. Myatt, and G. H. I Wolfgang.2001. Chem-tox informatics data mining using a medicinal chemistry building block approach. Curr. Opin. Drug Discov. Devel.4(1):92–101.
8.
Johnson, D. E., and G. H. I Wolfgang.2000. Predicting human safety: Screening and computational approaches. Drug Discov. Today5:445–454.
9.
Kallen, K.-J., J. Grötzinger, and S. Rose-John. 2000. New perspectives on the design of cytokines and growth factors. Trends in Biotechnol.18(11):455–461.
10.
Leibbrandt, M. E. I.2000. Safety evaluation of gene therapy viral vectors. Curr. Opin. Drug Discov. Devel.3:48–55.
11.
PriceWaterhouseCoopers. 1999. An industrial revolution in R&D. Pharma 2000.
12.
PhRMA. 2000. Pharmaceutical innovation and health (www.phrma.org).
13.
Reichert, J. M.2000. New biopharmaceuticals in the USA: Trends in development and marketing approvals 1995–1999. TIBTECH.18:364–369.
14.
Roberts, G., G. J. Myatt, W. P. Johnson, K. P. Cross, and P. E. Blower.2000. LeadScope: Software for exploring large sets of screening data. J. Chem. Inf. Compu. Sci.40:1302–1314.
15.
Serabian, M. A., and A. M. Pilaro.1999. Safety assessment of biotechnology-derived pharmaceuticals: ICH and beyond. Toxicol. Pathol.27:27–31.
16.
Wolfgang, G. H. I., D. E. Johnson, G. Roberts, W. Snyder, G. J. Myatt, and P. E. Blower. 2001. Computational toxicology and virtual development in drug design. J. Mol. Graphics Model. In press.
